How much funding has Upstream Bio raised?

Upstream Bio has raised $400.0M in total funding, most recently a Series B round.

Who are Upstream Bio's investors?

Upstream Bio's investors include OrbiMed, Maruho Co., Ltd., Enavate Sciences, Venrock, Bain Capital Life Sciences, Wellington Management.

When was Upstream Bio founded?

Upstream Bio was founded in 2021.

Where is Upstream Bio headquartered?

Upstream Bio is headquartered in Waltham, Massachusetts, United States.

What industry is Upstream Bio in?

Upstream Bio operates in Biotech, Healthcare.

How many employees does Upstream Bio have?

Upstream Bio has 51-200 employees.

Upstream Bio

IPO

Homepage

Public · Waltham, United States · Founded 2021 · $400.0M raised

Biotech

Healthcare

Headquarters: Waltham, Massachusetts
Employees: 51–200
Founded: 2021
Business Model: B2B
Website: upstreambio.com

Total Funding: $400.0M
Last Round: $200.0M Series BJun 2023
Rounds: 2
Type: Public

About

Upstream Bio is a clinical-stage biotechnology company developing verekitug, the only known TSLP receptor antagonist in clinical development for inflammatory diseases. The company has advanced verekitug into three Phase 2 clinical trials across chronic rhinosinusitis with nasal polyps, severe asthma, and COPD, with an experienced team focused on severe respiratory diseases.

Summary

Upstream Bio is a Biotech company based in Waltham, United States, founded in 2021. It has raised $400.0M in total across 2 rounds, most recently a $200.0M Series B round in Jun 2023. Investors include OrbiMed, Maruho Co., Ltd. and Enavate Sciences.

LinkedIn X (Twitter)